MeiraGTx to Participate in Upcoming Virtual Investor Conferences

Rhea-AI Summary

MeiraGTx Holdings (NASDAQ: MGTX), a clinical stage gene therapy company, announced participation in upcoming virtual investor conferences. Key presentations include:

• Barclays Gene Editing & Gene Therapy Summit on November 15, 2021, at 2:00 p.m. ET.
• 33rd Annual Piper Sandler Healthcare Conference available from November 22 to December 2, 2021.
• Evercore ISI 4th Annual HealthCONx on November 30, 2021, at 10:05 a.m. ET.

Webcasts of these events will be accessible on their Investors page for 30 days post-presentation.

LONDON and NEW YORK, Nov. 09, 2021 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D., President and Chief Executive Officer, will participate in the following virtual investor conferences:

• Barclays Gene Editing & Gene Therapy Summit
  

Corporate presentation: Monday, November 15, 2021, at 2:00 p.m. ET

• 33^rd Annual Piper Sandler Healthcare Conference

Fireside chat: available from Monday, November 22, 2021, at 10:00 a.m. ET to Thursday, December 2, 2021 for registered attendees via the Piper Sandler conference site.

• Evercore ISI 4^th Annual HealthCONx
  

Corporate presentation: Tuesday, November 30, 2021, at 10:05 a.m. ET

A live webcast of the corporate presentations and the recording of the Piper Sandler fireside chat will be available on the Investors page of the Company’s website at investors.meiragtx.com. Replays will be available for approximately 30 days following the presentation dates.

About MeiraGTx
MeiraGTx (Nasdaq: MGTX) is a vertically integrated, clinical stage gene therapy company with six programs in clinical development and a broad pipeline of preclinical and research programs. MeiraGTx has core capabilities in viral vector design and optimization and gene therapy manufacturing, as well as a potentially transformative gene regulation technology. Led by an experienced management team, MeiraGTx has taken a portfolio approach by licensing, acquiring and developing technologies that give depth across both product candidates and indications. MeiraGTx’s initial focus is on three distinct areas of unmet medical need: ocular, including inherited retinal diseases and large degenerative diseases, neurodegenerative diseases and severe forms of xerostomia. Though initially focusing on the eye, central nervous system and salivary gland, MeiraGTx intends to expand its focus in the future to develop additional gene therapy treatments for patients suffering from a range of serious diseases.

For more information, please visit www.meiragtx.com.

Contacts

Investors:
MeiraGTx
Investors@meiragtx.com

(646) 860-7982

Media:
Jason Braco, Ph.D.
LifeSci Communications
jbraco@lifescicomms.com

FAQ

What events is MeiraGTx (MGTX) participating in November 2021?

MeiraGTx is participating in the Barclays Gene Editing & Gene Therapy Summit on November 15, the Piper Sandler Healthcare Conference from November 22 to December 2, and the Evercore ISI HealthCONx on November 30, 2021.

When will MeiraGTx's corporate presentation at the Barclays Summit take place?

The corporate presentation at the Barclays Gene Editing & Gene Therapy Summit is scheduled for November 15, 2021, at 2:00 p.m. ET.

How can I access MeiraGTx's presentations from their investor conferences?

Webcasts of MeiraGTx's presentations will be available on the Investors page of their website for approximately 30 days after the events.

What is the schedule for the Piper Sandler Healthcare Conference participation by MGTX?

MeiraGTx will have a fireside chat available from November 22 to December 2, 2021, for registered attendees at the Piper Sandler Healthcare Conference.

What time is MeiraGTx's presentation at the Evercore ISI HealthCONx?

MeiraGTx's corporate presentation at the Evercore ISI 4th Annual HealthCONx is on November 30, 2021, at 10:05 a.m. ET.